Erratum to "Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy" [J. Cardiol. 53 (2009), 72-78] (DOI:10.1016/j.jjcc.2008.08.013);Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy

Journal of Cardiology

Volumn 53, Issue 1, 2009, Pages 72-78

  Ogata, Hitoko ^a   Ishikawa, Yuka ^a   Ishikawa, Yukitoshi ^a   Minami, Ryoji ^a  

^a National Hospital Organization   (Japan)

Author keywords

Angiotensin converting enzyme inhibitor; Beta blocker; Cardiomyopathy; Duchenne muscular dystrophy; Heart failure

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; LISINOPRIL; METOPROLOL;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DUCHENNE MUSCULAR DYSTROPHY; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE; RETROSPECTIVE STUDIES; SURVIVAL RATE; VENTRICULAR DYSFUNCTION, LEFT; YOUNG ADULT;

EID: 58249134742     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2009.02.001     Document Type: Erratum

References (24)

1. Brooke M.H., Fenichel G.M., Griggs R.C., Mendell J.R., Moxley R., Florence J., et al. Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology 39 (1989) 475-481
2. Cox G.F., and Kunkel L.M. Dystrophies and heart disease. Curr Opin Cardiol 12 (1997) 329-343
3. Hilton T., Orr R.D., Perkin R.M., and Ashwal S. End of life care in Duchenne muscular dystrophy. Pediatr Neurol 9 (1993) 165-177
4. Ishikawa Y., Bach J.R., Sarma R.J., Tamura T., Song J., Marra S.W., et al. Cardiovascular considerations in the management of neuromuscular disease. Semin Neurol 15 (1995) 93-108
5. Eagle M., Baudouin S.V., Chandler C., Giddings D.R., Bullock R., and Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 12 (2002) 926-929
6. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 (1996) 1349-1355
7. CIBIS II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS II): a randomized trial. Lancet 353 (1999) 9-13
8. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 353 (1999) 2001-2007
9. Packer M., Coats A.J.S., Fowler M.B., Katus H.A., Krum H., Mohacsi P., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
10. Doughty R.N., Rogers A., Sharpe N., and MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. A systemic overview of randomized controlled trials. Eur Heart J 18 (1997) 560-565
11. Heidenreich P.A., Lee T.T., and Massie B.M. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 30 (1997) 27-34
12. Remme W.J., and Swedberg K. Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 22 (2001) 1527-1560
13. Exner D.V., Dries D.L., Waclawiw M.A., Shelton B., and Domanski M.J. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction. J Am Coll Cardiol 33 (1999) 916-923
14. Vantrimpont P., Rouleau J.L., Wun C.C., Ciampi A., Klein M., Sussex B., et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. J Am Coll Cardiol 29 (1997) 229-236
15. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francs G.S., Ganiats T.G., et al. ACC/AHA 2005 guideline update for diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 guidelines for the evaluation and management of heart failure). Circulation 112 (2005) e154-e235
16. Ishikawa Y., Bach J.R., and Minami R. Cardioprotection for Duchenne's muscular dystrophy. Am Heart J 137 (1999) 895-902
17. Ishihara Y., Tamura T., Nishimura T., Kawamura J., and Kawashiro T. Prognosis of chronic left ventricular dysfunction in Duchenne muscular dystrophy. Annual report of the research on nervous and mental disorders 1997 (1997), National Center of Neurology and Psychiatry, Tokyo p. 92
18. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 (1987) 1429-1435
19. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
20. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327 (1992) 685-691
21. Garg R., Yusuf S., and For the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 273 (1995) 1450-1456
22. Towbin J.A. A noninvasive means of detecting preclinical cardiomyopathy in Duchenne muscular dystrophy?. J Am Coll Cardiol 42 (2003) 317-318
23. Duboc D., Meune C., Lerebours G., Devaux J.Y., Vaksmann G., and Bécane H.M. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 45 (2005) 855-857
24. Simonds A.K. Recent advances in respiratory care for neuromuscular disease. Chest 130 (2006) 1879-1886